Monocyte responses in adults with type 1 diabetes and chronic kidney disease
Official title: Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
Run by The Cleveland Clinic · NCT06694558 · Data updated 2026-11-12
This study will test whether time-in-range changes how monocytes become activated in adults with type 1 diabetes and chronic kidney disease and whether a GLP-1 drug can reduce that activation in lab tests.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | December 30, 2026 |
| Study ends | July 1, 2027 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT06694558 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–65 with type 1 diabetes on insulin and using a continuous glucose monitor, either with CKD (eGFR 60–90 ml/min/1.73 m2 and UACR 30–500 mg/g) or as controls without CKD (eGFR >90 and UACR <30 mg/g).
✕Probably not a fit
People already taking GLP-1 agonists, DPP-4 inhibitors, or SGLT2 inhibitors, those with hemoglobin <9 g/dL, those not using a CGM, or individuals outside the 18–65 age range are unlikely to be eligible or to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional study comparing monocyte responses from adults with type 1 diabetes who have CKD to those without CKD. Participants will be stratified by continuous glucose monitor time-in-range (lower <60% vs higher >70%) and provide a blood sample during a single study visit. Monocytes will be studied ex vivo for activation and effects on podocytes, and investigators will test whether a GLP-1 agonist attenuates monocyte activation in laboratory assays. Subjects are recruited from the Cleveland Clinic and the community and may be asked to return for a repeat blood draw if initial samples do not yield enough cells.
Why it matters
Potential benefit: If successful, this work could point to time-in-range and GLP-1–related pathways as targets to reduce inflammatory processes that may worsen kidney injury in people with type 1 diabetes.
How similar studies have gone: Prior clinical and laboratory studies have reported anti-inflammatory and kidney-protective effects of GLP-1 drugs in diabetes, but applying ex vivo monocyte activation assays specifically in type 1 diabetes with CKD is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. T1D CKD subjects: 1. Adults, males or females diagnosed with T1D 2. Age 18-65 years 3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2) 4. Diagnosed with albuminuria (UACR 30-500 mg/g) 5. On insulin injections or pump 6. On CGM Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0 2. Controls: T1D subjects without CKD 1. Adults, males or females diagnosed with T1D 2. Age 18-65 years 3. No CKD (eGFR \>90 ml/min/1.73 m2) 4. No albuminuria (UACR \<30 mg/g) 5. On insulin injections or pump 6. On CGM Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0 Exclusion Criteria: 1. Hemoglobin \<9 2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days 3. pregnancy or plans to become pregnant 4. On steroids 5. Diagnosed with cancer, immunosuppression/autoimmune conditions 6. Reported heavy alcohol use or recreational drug use 7. Any condition which jeopardizes patient safety or affects monocytes at physician's discretion
Where it's running
-
Cleveland Clinic
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Rong M Zhang, MD — The Cleveland Clinic
- Study coordinator: Andrea Debs
- Email: debsa@ccf.org
- Phone: 216-445-8354
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Benefits of Retained Insulin for Good Health in Diabetes
This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.
-
Intermittent CGM Use in high-risk children and teens with Type 1 Diabetes in the Dominican Republic
This study tests whether using the Dexcom G7 intermittently, along with pediatric care and support, can improve glucose control in 10–19 year-olds with high-risk Type 1 Diabetes in the Dominican Republic.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
-
Dietary changes to help adults with Type 1 diabetes and overweight see if moderate carbs, time-restricted eating, or regular calories work
We’re testing three weight-loss approaches in adults with type 1 diabetes who are overweight or obese to see which helps reduce weight safely.
-
Islet re-transplantation after prior graft failure in adults with type 1 diabetes
This study looks at whether giving another islet transplant after a prior failed graft helps adults with type 1 diabetes who have severe swings in blood sugar.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.